肿瘤委员会会议在神经肿瘤学中的作用:一项全国性提供者调查
该横断面描述性调查通过互联网问卷覆盖85家美国神经肿瘤中心,发现多学科肿瘤会议核心学科参与一致,讨论病例以原发脑肿瘤(100%)为主,会议被认为对临床决策(94%)和教育(89%)有价值,但准备时间和建议实施存在差异,分子肿瘤委员会定义存在高度不确定性。
要点
- 多学科肿瘤会议讨论原发脑肿瘤(100%)、疑难病例(98%)和复发疾病(96%)。
- 会议核心学科为神经肿瘤科、神经外科和放射肿瘤科(100%),放射科(98%)和病理科(96%)参与。
- 会议被认为对临床决策(94%)和教育(89%)有价值,仅13%在病历中记录会议。
核心结论
- 美国领先机构的神经肿瘤多学科会议在核心学科、讨论病例和感知价值方面表现一致,但准备时间和会议建议的实施存在差异,分子肿瘤委员会的定义和应用存在高度不确定性。
研究设计与样本
- 横断面描述性调查通过互联网问卷发放,纳入85家中心,包括所有美国国家癌症研究所指定中心以及成人脑肿瘤联盟或脑肿瘤试验协作组的参与中心。
主要发现
- 讨论内容包括原发脑肿瘤(100%)、疑难病例(98%)、复发疾病(96%)、肿瘤性脊柱疾病(93%)、转移性脑病变(89%)、术前病例(82%)、病理(76%)和副肿瘤性疾病(40%)。
- 会议组成包括神经肿瘤科医生、神经外科医生和放射肿瘤科医生(100%)、放射科医生(98%)、病理科医生(96%)和临床试验参与者(64%)。
- 个人准备时间为15至300分钟。
- 会议被认为对临床决策(94%)、教育(89%)和临床试验获取(69%)有价值。
- 13%的中心在病历中记录多学科会议,38%的中心使用分子肿瘤委员会,但许多评论者对定义存在不确定性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The tumor board or multidisciplinary cancer meeting (MCM) is the foundation of high value multidisciplinary oncology care, coordinating teams of specialists. Little is known on how these meetings are implemented in Neuro-oncology. Benefits of MCMs include coordination, direction for complicated cases, education, and a forum for communication, emerging technology, and clinical trials. This study identifies participation and utilization of neuro-oncology MCMs. A cross-sectional descriptive survey was dispersed through an internet questionnaire. The Society of Neuro-Oncology and the American Brain Tumor Association provided a list of dedicated neuro-oncology centers. All National Cancer Institute designated centers, and participants in the Adult Brain Tumor Consortium or the Brain Tumor Trials Collaborative were included, identifying 85 centers. Discussion included primary brain tumors (100%), challenging cases (98%), recurrent disease (96%), neoplastic spine disease (93%), metastatic brain lesions (89%), pre-surgical cases (82%), pathology (76%), and paraneoplastic disease (40%). MCMs were composed of neuro-oncologists, neurosurgeons, and radiation oncologists (100%), radiologists (98%), pathologists (96%), and clinical trial participants (64%). Individual preparation ranged from 15 to 300 min. MCMs were valued for clinical decision making (94%), education (89%), and access to clinical trials (69%). 13% documented MCMs in the medical record. 38% of centers used a molecular tumor board; however, many commented with uncertainty as to how this is defined. Neuro-oncology MCMs at leading U.S. institutions demonstrate congruity of core disciplines, cases discussed, and perceived value. We identified variability in preparation time and implementation of MCM recommendations. There is high uncertainty as to the definition and application of a molecular tumor board.
引用
- Snyder J, Schultz L, Walbert T, et al. The role of tumor board conferences in neuro-oncology: a nationwide provider survey. J Neurooncol. 2017. PMID: 28421461. doi:10.1007/s11060-017-2416-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。